Jonathan E. Lim - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
Director
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
30 Jan 2025
Net transactions value
$0
Form type
3
Filing time
30 Jan 2025, 16:34:12 UTC
Previous filing
21 Jun 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MAZE Common Stock 20,744 30 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MAZE Series A Preferred Stock 30 Jan 2025 Common Stock 363,703 City Hill, LLC F1, F2
holding MAZE Series B Preferred Stock 30 Jan 2025 Common Stock 2,231,381 City Hill, LLC F2, F3
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 5,704 $10.42 Direct F4
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 9,086 $10.42 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for- 0.1037236801. The securities have no expiration date.
F2 These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
F3 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series B Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date.
F4 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F5 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.